齐泊腾坦联合达格列净对比达格列净治疗慢性肾脏病患者(ZENITH-CKD):一项多中心、随机、活性对照、2b期临床试验
ZENITH-CKD是在18个国家170个临床实践中心开展的多中心、随机、双盲、活性对照2b期试验,纳入eGFR≥20 mL/min/1.73 m²且尿白蛋白/肌酐比值150-5000 mg/g的成人慢性肾脏病患者449例。12周时,齐泊腾坦1.5 mg联合达格列净组与达格列净加安慰剂组相比UACR差异为-33.7%(90%CI -42.5至-23.5;p<0.0001),齐泊腾坦0.25 mg联合达格列净组差异为-27.0%(90%CI -38.4至-13.6;p=0.0022)。作者认为齐泊腾坦联合达格列净降低白蛋白尿且耐受性和安全性可接受。
要点
- 12周时齐泊腾坦1.5 mg联合达格列净较达格列净加安慰剂降低UACR 33.7%(90%CI -42.5至-23.5;p<0.0001)。
- 12周时齐泊腾坦0.25 mg联合达格列净较达格列净加安慰剂降低UACR 27.0%(90%CI -38.4至-13.6;p=0.0022)。
- 液体潴留事件发生率:齐泊腾坦1.5 mg组18%(33/179)、0.25 mg组9%(8/91)、达格列净加安慰剂组8%(14/177)。
核心结论
- 齐泊腾坦联合达格列净降低白蛋白尿,耐受性和安全性可接受,是已接受当前推荐治疗的慢性肾脏病患者减少疾病进展的一种选择。
研究设计与样本
- 多中心、随机、双盲、活性对照2b期临床试验,在18个国家170个临床实践中心开展。
- 纳入年龄≥18至≤90岁、eGFR≥20 mL/min/1.73 m²且UACR 150-5000 mg/g的成人慢性肾脏病患者。
- 按2:1:2随机分配至每日齐泊腾坦1.5 mg联合达格列净10 mg组(n=179)、齐泊腾坦0.25 mg联合达格列净10 mg组(n=91)或达格列净10 mg加安慰剂组(n=177),治疗12周,在耐受情况下作为ACEI或ARB的辅助治疗。
- 主要终点为第12周log转换UACR较基线的变化(齐泊腾坦1.5 mg联合达格列净 vs 达格列净加安慰剂)。
- 2021年4月28日至2023年1月17日评估1492例参与者资格,主要分析随机分配449例(30%),其中447例(99%)接受治疗。
主要发现
- 接受治疗人群平均年龄62.8岁(SD 12.1),女性138例(31%)、男性309例(69%),白人305例(68%),平均eGFR 46.7 mL/min/1.73 m²(SD 22.4),中位UACR 565.5 mg/g(IQR 243.0-1212.6)。
- 整个治疗期间,齐泊腾坦1.5 mg联合达格列净和齐泊腾坦0.25 mg联合达格列净均较达格列净加安慰剂降低UACR。
- 第12周UACR较达格列净加安慰剂的差异:齐泊腾坦1.5 mg联合达格列净组为-33.7%(90%CI -42.5至-23.5;p<0.0001),齐泊腾坦0.25 mg联合达格列净组为-27.0%(90%CI -38.4至-13.6;p=0.0022)。
- 液体潴留事件:齐泊腾坦1.5 mg联合达格列净组179例中33例(18%),齐泊腾坦0.25 mg联合达格列净组91例中8例(9%),达格列净加安慰剂组177例中14例(8%)。
关键数值与推荐
- 液体潴留为特别关注事件,定义为体重较基线增加至少3%(其中至少2.5%必须来自总体水)或B型利钠肽(BNP)增加至少100%且无房颤时BNP>200 pg/mL或有房颤时BNP>400 pg/mL。
- 主要终点第12周UACR较达格列净加安慰剂差异:齐泊腾坦1.5 mg联合达格列净组-33.7%(90%CI -42.5至-23.5;p<0.0001);齐泊腾坦0.25 mg联合达格列净组-27.0%(90%CI -38.4至-13.6;p=0.0022)。
临床怎么用
- 作者认为,齐泊腾坦联合达格列净降低白蛋白尿且耐受性和安全性可接受,是已接受当前推荐治疗的慢性肾脏病患者减少疾病进展的一种选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with chronic kidney disease, SGLT2 inhibitors and endothelin A receptor antagonists (ERAs) can reduce albuminuria and glomerular filtration rate (GFR) decline. We assessed the albuminuria-lowering efficacy and safety of the ERA zibotentan combined with the SGLT2 inhibitor dapagliflozin. METHODS: ZENITH-CKD was a multicentre, randomised, double-blind, active-controlled clinical trial, done in 170 clinical practice sites in 18 countries. Adults (≥18 to ≤90 years) with an estimated GFR (eGFR) of 20 mL/min per 1·73 m2 or greater and a urinary albumin-to-creatinine ratio (UACR) of 150-5000 mg/g were randomly assigned (2:1:2) to 12 weeks of daily treatment with zibotentan 1·5 mg plus dapagliflozin 10 mg, zibotentan 0·25 mg plus dapagliflozin 10 mg, or dapagliflozin 10 mg plus placebo, as adjunct to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers if tolerated. The primary endpoint was a change from baseline in log-transformed UACR (zibotentan 1·5 mg plus dapagliflozin vs dapagliflozin plus placebo) at week 12. Fluid retention was an event of special interest, defined as an increase in bodyweight of at least 3% (at least 2·5% must have been from total body water) from baseline or an increase of at least 100% in B-type natriuretic peptide (BNP) and either a BNP concentration greater than 200 pg/mL if without atrial fibrillation or BNP greater than 400 pg/mL if with atrial fibrillation. This trial is registered with ClinicalTrials.gov, NCT04724837, and is completed. FINDINGS: Between April 28, 2021, and Jan 17, 2023, we assessed 1492 participants for eligibility. For the main analysis, we randomly assigned 449 (30%) participants, 447 (99%) of whom (mean age 62·8 years [SD 12·1], 138 [31%] female, 309 [69%] male, 305 [68%] White, mean eGFR 46·7 mL/min per 1·73 m2 [SD 22·4], and median UACR 565·5 mg/g [IQR 243·0-1212·6]) received treatment with zibotentan 1·5 mg plus dapagliflozin (n=179 [40%]), zibotentan 0·25 mg plus dapagliflozin (n=91 [20%]), or dapagliflozin plus placebo (n=177 [40%]). Zibotentan 1·5 mg plus dapagliflozin and zibotentan 0·25 mg plus dapagliflozin reduced UACR versus dapagliflozin plus placebo throughout the treatment period of the study. At week 12, the difference in UACR versus dapagliflozin plus placebo was -33·7% (90% CI -42·5 to -23·5; p<0·0001) for zibotentan 1·5 mg plus dapagliflozin and -27·0% (90% CI -38·4 to -13·6; p=0·0022) for zibotentan 0·25 mg plus dapagliflozin. Fluid-retention events were observed in 33 (18%) of 179 participants in the zibotentan 1·5 mg plus dapagliflozin group, eight (9%) of 91 in the zibotentan 0·25 mg plus dapagliflozin group, and 14 (8%) of 177 in the dapagliflozin plus placebo group. INTERPRETATION: Zibotentan combined with dapagliflozin reduced albuminuria with an acceptable tolerability and safety profile and is an option to reduce chronic kidney disease progression in patients already receiving currently recommended therapy. FUNDING: AstraZeneca.
引用
- Heerspink HJL, Kiyosue A, Wheeler DC, et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet. 2023. PMID: 37931629. doi:10.1016/S0140-6736(23)02230-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。